comparemela.com

Latest Breaking News On - Network of companies - Page 1 : comparemela.com

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare ...

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Corey-davis
Dineshv-patel
Protagonist-therapeutics-inc
Johnson
Network-of-companies
News-network
Protagonist-therapeutics
Chief-executive-officer
Jefferies-global-healthcare-conference
New-york-city
Global-healthcare-conference
Johnson-innovative-medicine

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Dineshv-patel
Corey-davis
Network-of-companies
Johnson
Protagonist-therapeutics-inc
Protagonist-therapeutics
Chief-executive-officer
Jefferies-global-healthcare-conference
New-york-city
Johnson-innovative-medicine
New-england-journal

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio.

Ann-arbor
Michigan
United-states
Spain
Madrid
Hall-goya
Kristenm-pettit
Corey-davis
Division-of-hematology-oncology
Department-of-internal-medicine
Network-of-companies
University-of-michigan

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Madrid
Spain
United-states
Michigan
Ann-arbor
Hall-goya
Kristenm-pettit
Corey-davis
Department-of-internal-medicine
Division-of-hematology-oncology
Nasdaq
Protagonist-therapeutics-inc

vimarsana © 2020. All Rights Reserved.